From the early days of MS discovery, infections have been proposed as a possible cause of the disease. In the last three decades, an association between human endogenous retrovirus expression and MS has been further investigated and confirmed. Nevertheless, the role of such retroviruses in the disease needs clarification. In this review, we introduce MSRV/HERV-W and describe its association with MS. We then summarize the evidence for the involvement of MSRV/HERV-W in the aetiology and progression of MS and its possible role as biomarker and drug target. Biological mechanisms for HERV effects in MS may involve the activation of innate immune pathways by the envelope protein of MSRV (MSRVEnv). In addition to in vitro and experimental studies, further insight on how HERVs may influence immune-mediated pathology in MS may also come from the use of antiretroviral treatments in patients.
KurtzkeJF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev1993; 6: 382–427.
2.
AscherioAMungerKL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol2007; 61: 288–299.
3.
PoskanzerDCWalkerAMYonkondyJ. Studies in the epidemiology of multiple sclerosis in the Orkney and Shetland Islands. Neurology1976; 26: 14–17.
4.
VoissetCWeissRAGriffithsDJ. Human RNA ‘rumor’ viruses: The search for novel human retroviruses in chronic disease. Microbio Mol Bio Rev2008; 72: 157–196.
5.
PerronHGarsonJABedinF. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci U S A1997; 94: 7583–7588.
6.
GrandiNCadedduMBlombergJ. Contribution of type W human endogenous retroviruses to the human genome: Characterization of HERV-W proviral insertions and processed pseudogenes. Retrovirology2016; 13: 67.
7.
MorandiETanasescuRTarlintonRE. The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. PLoS ONE2017; 12: e0172415.
8.
MorandiETarlintonREGranB. Multiple sclerosis between genetics and infections: Human endogenous retroviruses in monocytes and macrophages. Front Immunol2015; 6: 647.
9.
MameliGPoddigheLMeiA. Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: Inference for multiple sclerosis. PLoS ONE2012; 7: e44991.
10.
MameliGAstoneVArruG. Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not human herpesvirus 6. J Gen Virol2007; 88: 264–274.
11.
PerronHLazariniFRuprechtK. Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol2005; 11: 23–33.
12.
SchmittKRichterCBackesC. Comprehensive analysis of human endogenous retrovirus group HERV-W locus transcription in multiple sclerosis brain lesions by high-throughput amplicon sequencing. J Virol2013; 87: 13837–13852.
13.
AntonyJMZhuYIzadM. Comparative expression of human endogenous retrovirus-W genes in multiple sclerosis. AIDS Res Hum Retroviruses2007; 23: 1251–1256.
14.
StoyeJP. Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat Rev Microbiol2012; 10: 395–406.
15.
KucukaliCIKurtuncuMCobanA. Epigenetics of multiple sclerosis: An updated review. Neuromolecular Med2015; 17: 83–96.
16.
NexoBAHansenBNissenKK. Restriction genes for retroviruses influence the risk of multiple sclerosis. PLoS ONE2013; 8: e74063.
17.
DoleiAPerronH. The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: A biological interface between virology, genetics, and immunology in human physiology and disease. J Neurovirol2009; 15: 4–13.
18.
MameliGMadedduGMeiA. Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: The missing link with multiple sclerosis?PLoS ONE2013; 8: e78474.
19.
SaresellaMRollandAMarventanoI. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Mult Scler2009; 15: 443–447.
20.
RollandAJouvin-MarcheEViretC. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol2006; 176: 7636–7644.
21.
DuperrayABarbeDRaguenezG. Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. Int Immunol2015; 27: 545–553.
22.
KremerDSchichelTForsterM. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol2013; 74: 721–732.
23.
PerronHJouvin-MarcheEMichelM. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virol2001; 287: 321–332.
24.
FirouziRRollandAMichelM. Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovirol2003; 9: 79–93.
25.
HummelJKammererUMullerN. Human endogenous retrovirus envelope proteins target dendritic cells to suppress T-cell activation. Eur J Immunol2015; 45: 1748–1759.
26.
PerronHDougier-ReynaudHLLomparskiC. Human endogenous retrovirus protein activates innate immunity and promotes experimental allergic encephalomyelitis in mice. PLoS ONE2013; 8: e80128.
27.
HsiaoFCTaiAKDeglonA. EBV LMP-2A employs a novel mechanism to transactivate the HERV-K18 superantigen through its ITAM. Virol2009; 385: 261–266.
28.
SotgiuSMameliGSerraC. Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler2010; 16: 1248–1251.
29.
ArruGLeoniSPugliattiM. Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: A longitudinal cohort study. Mult Scler2013; 20: 174–182.
30.
MameliGSerraCAstoneV. Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurovirol2008; 14: 73–77.
31.
CurtinFPerronHFaucardR. Treatment against human endogenous retrovirus: A possible personalized medicine approach for multiple sclerosis. Mol Diagn Ther2015; 19: 255–265.
32.
CurtinFLangABPerronH. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: A first-in-humans randomized clinical study. Clin Ther2012; 34: 2268–2278.
33.
DerfussTCurtinFGuebelinC. A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients – a twelve month follow-up. J Neuroimmunol2015; 285: 68–70.
34.
ZimmermannMSandersonNSRasenackM. Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS. Neurol Neuroimmunol Neuroinflamm2015; 2: e144.
35.
GoldJGoldacreRMaruszakH. HIV and lower risk of multiple sclerosis: Beginning to unravel a mystery using a record-linked database study. J Neurol Neurosurg Psychiatry2015; 86: 9–12.
36.
Zandman-GoddardGShoenfeldY. HIV and autoimmunity. Autoimmun Rev2001; 1: 329–337.
37.
DelgadoSRMaldonadoJRammohanKW. CNS demyelinating disorder with mixed features of neuromyelitis optica and multiple sclerosis in HIV-1 infection. Case report and literature review. J Neurovirol2014; 20: 531–537.
38.
ChinJH. Multiple sclerosis and HIV-1 infection: Case report of a HIV controller. J Neurovirol2015; 21: 464–467.
39.
Gonzalez-DuarteARamirezCPinalesR. Multiple sclerosis typical clinical and MRI findings in a patient with HIV infection. J Neurovirol2011; 17: 504–508.
40.
MaruszakHBrewBJGiovannoniG. Could antiretroviral drugs be effective in multiple sclerosis? A case report. Eur J Neurol2011; 18: e110–e111.
41.
ChalkleyJBergerJR. Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man. J Neurovirol2014; 20: 640–643.
42.
MartaMMacManusDYousryT. Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: The INSPIRE study results (Poster abstract P447). London: ECTRIMS.
